TY - JOUR
T1 - Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
T2 - A nested case-control study
AU - Huang, Jiaqi
AU - Zagai, Ulrika
AU - Hallmans, Göran
AU - Nyrén, Olof
AU - Engstrand, Lars
AU - Stolzenberg-Solomon, Rachael
AU - Duell, Eric J
AU - Overvad, Kim
AU - Katzke, Verena A
AU - Kaaks, Rudolf
AU - Jenab, Mazda
AU - Park, Jin Young
AU - Murillo, Raul
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Bamia, Christina
AU - Bradbury, Kathryn E
AU - Riboli, Elio
AU - Aune, Dagfinn
AU - Tsilidis, Konstantinos K.
AU - Capellá, Gabriel
AU - Agudo, Antonio
AU - Krogh, Vittorio
AU - Palli, Domenico
AU - Panico, Salvatore
AU - Weiderpass, Elisabete
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Martínez, Begoña
AU - Redondo-Sanchez, Daniel
AU - Chirlaque, Maria Dolores
AU - HM Peeters, Petra
AU - Regnér, Sara
AU - Lindkvist, Björn
AU - Naccarati, Alessio
AU - Ardanaz, Eva
AU - Larrañaga, Nerea
AU - Boutron-Ruault, Marie-Christine
AU - Rebours, Vinciane
AU - Barré, Amélie
AU - Bueno-De-Mesquita, Bas H.
AU - Ye, Weimin
PY - 2017/4/15
Y1 - 2017/4/15
N2 - The association between H. pylori infection and pancreatic cancer risk remains controversial. We conducted a nested case-control study with 448 pancreatic cancer cases and their individually matched control subjects, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, to determine whether there was an altered pancreatic cancer risk associated with H. pylori infection and chronic corpus atrophic gastritis. Conditional logistic regression models were applied to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs), adjusted for matching factors and other potential confounders. Our results showed that pancreatic cancer risk was neither associated with H. pylori seropositivity (OR = 0.96; 95% CI: 0.70, 1.31) nor CagA seropositivity (OR = 1.07; 95% CI: 0.77, 1.48). We also did not find any excess risk among individuals seropositive for H. pylori but seronegative for CagA, compared with the group seronegative for both antibodies (OR = 0.94; 95% CI: 0.63, 1.38). However, we found that chronic corpus atrophic gastritis was non-significantly associated with an increased pancreatic cancer risk (OR = 1.35; 95% CI: 0.77, 2.37), and although based on small numbers, the excess risk was particularly marked among individuals seronegative for both H. pylori and CagA (OR = 5.66; 95% CI: 1.59, 20.19, p value for interaction < 0.01). Our findings provided evidence supporting the null association between H. pylori infection and pancreatic cancer risk in western European populations. However, the suggested association between chronic corpus atrophic gastritis and pancreatic cancer risk warrants independent verification in future studies, and, if confirmed, further studies on the underlying mechanisms.
AB - The association between H. pylori infection and pancreatic cancer risk remains controversial. We conducted a nested case-control study with 448 pancreatic cancer cases and their individually matched control subjects, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, to determine whether there was an altered pancreatic cancer risk associated with H. pylori infection and chronic corpus atrophic gastritis. Conditional logistic regression models were applied to calculate odds ratios (ORs) and corresponding 95% confidence intervals (CIs), adjusted for matching factors and other potential confounders. Our results showed that pancreatic cancer risk was neither associated with H. pylori seropositivity (OR = 0.96; 95% CI: 0.70, 1.31) nor CagA seropositivity (OR = 1.07; 95% CI: 0.77, 1.48). We also did not find any excess risk among individuals seropositive for H. pylori but seronegative for CagA, compared with the group seronegative for both antibodies (OR = 0.94; 95% CI: 0.63, 1.38). However, we found that chronic corpus atrophic gastritis was non-significantly associated with an increased pancreatic cancer risk (OR = 1.35; 95% CI: 0.77, 2.37), and although based on small numbers, the excess risk was particularly marked among individuals seronegative for both H. pylori and CagA (OR = 5.66; 95% CI: 1.59, 20.19, p value for interaction < 0.01). Our findings provided evidence supporting the null association between H. pylori infection and pancreatic cancer risk in western European populations. However, the suggested association between chronic corpus atrophic gastritis and pancreatic cancer risk warrants independent verification in future studies, and, if confirmed, further studies on the underlying mechanisms.
KW - chronic corpus atrophic gastritis
KW - EPIC cohort
KW - H. pylori infection
KW - nested case-control study
KW - pancreatic cancer risk
UR - http://www.scopus.com/inward/record.url?scp=85013381974&partnerID=8YFLogxK
U2 - 10.1002/ijc.30590
DO - 10.1002/ijc.30590
M3 - Article
C2 - 28032715
AN - SCOPUS:85013381974
SN - 0020-7136
VL - 140
SP - 1727
EP - 1735
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 8
ER -